These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 32681948)

  • 21. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation.
    Rosière R; Van Woensel M; Gelbcke M; Mathieu V; Hecq J; Mathivet T; Vermeersch M; Van Antwerpen P; Amighi K; Wauthoz N
    Mol Pharm; 2018 Mar; 15(3):899-910. PubMed ID: 29341619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy.
    Jin Z; Gao Q; Wu K; Ouyang J; Guo W; Liang XJ
    Adv Drug Deliv Rev; 2023 Nov; 202():115111. PubMed ID: 37820982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanotechnology approaches for inhalation treatment of lung diseases.
    Kuzmov A; Minko T
    J Control Release; 2015 Dec; 219():500-518. PubMed ID: 26297206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics.
    Pathak K; Keshri L; Shah M
    Crit Rev Ther Drug Carrier Syst; 2011; 28(4):357-93. PubMed ID: 21967401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanodrugs: pharmacokinetics and safety.
    Onoue S; Yamada S; Chan HK
    Int J Nanomedicine; 2014; 9():1025-37. PubMed ID: 24591825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical Pharmacology and Pharmacokinetics of Inhaled Hexadecyl-Treprostinil (C16TR), a Pulmonary Vasodilator Prodrug.
    Corboz MR; Li Z; Malinin V; Plaunt AJ; Konicek DM; Leifer FG; Chen KJ; Laurent CE; Yin H; Biernat MC; Salvail D; Zhuang J; Xu F; Curran A; Perkins WR; Chapman RW
    J Pharmacol Exp Ther; 2017 Dec; 363(3):348-357. PubMed ID: 28904003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled chemotherapy in lung cancer: future concept of nanomedicine.
    Zarogoulidis P; Chatzaki E; Porpodis K; Domvri K; Hohenforst-Schmidt W; Goldberg EP; Karamanos N; Zarogoulidis K
    Int J Nanomedicine; 2012; 7():1551-72. PubMed ID: 22619512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations.
    Ali Khan A; Mudassir J; Mohtar N; Darwis Y
    Int J Nanomedicine; 2013; 8():2733-44. PubMed ID: 23926431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary delivery of anti-inflammatory agents.
    Ali ME; McConville JT; Lamprecht A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):929-45. PubMed ID: 25534260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innovative formulations for controlled drug delivery to the lungs and the technical and toxicological challenges to overcome(.).
    Aragao-Santiago L; Bohr A; Delaval M; Dalla-Bona AC; Gessler T; Seeger W; Beck-Broichsitter M
    Curr Pharm Des; 2016; 22(9):1147-60. PubMed ID: 26675224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications.
    Rudokas M; Najlah M; Alhnan MA; Elhissi A
    Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):60-72. PubMed ID: 26938856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.
    Shahin HI; Vinjamuri BP; Mahmoud AA; Shamma RN; Mansour SM; Ammar HO; Ghorab MM; Chougule MB; Chablani L
    J Control Release; 2019 May; 302():126-139. PubMed ID: 30940497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems.
    Woods A; Andrian T; Sharp G; Bicer EM; Vandera KA; Patel A; Mudway I; Dailey LA; Forbes B
    Eur J Pharm Biopharm; 2020 Jan; 146():64-72. PubMed ID: 31756380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selected Engineering and Physicochemical Aspects of Systemic Drug Delivery by Inhalation.
    Sosnowski TR
    Curr Pharm Des; 2016; 22(17):2453-62. PubMed ID: 26818874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects.
    Gulati N; Chellappan DK; MacLoughlin R; Dua K; Dureja H
    Life Sci; 2021 Nov; 285():119969. PubMed ID: 34547339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.
    Iyer R; Hsia CC; Nguyen KT
    Curr Pharm Des; 2015; 21(36):5233-44. PubMed ID: 26412358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberculosis Treatment Facilitated by Lipid Nanocarriers: Can Inhalation Improve the Regimen?
    Hädrich G; Boschero RA; Appel AS; Falkembach M; Monteiro M; da Silva PEA; Dailey LA; Dora CL
    Assay Drug Dev Technol; 2020 Oct; 18(7):298-307. PubMed ID: 33054379
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of inhaled drugs.
    Lipworth BJ
    Br J Clin Pharmacol; 1996 Dec; 42(6):697-705. PubMed ID: 8971424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.